The AXIS Registry is a 10-year Longitudinal Research Initiative That Captures the Real-world Experiences of People Living With Autoimmune Neurology Conditions. Launching in Myasthenia Gravis (MG), we Plan to Evaluate Expansion to Other Conditions Across Autoimmune Neurology.

Part of paid clinical trials in Framingham, Massachusetts.

Sponsor
Autoimmune Neurology Alliance
Study ID
NCT07761026
Status
Recruiting
Apply to this trial

Conditions

  • AChR Myasthenia Gravis
  • AChR-Ab Seropositive Generalized Myasthenia Gravis
  • MG
  • MG - Myasthenia Gravis
  • Myasthenia Gravis
  • Myasthenia Gravis (MG)
  • Myasthenia Gravis Associated With Thymoma
  • Myasthenia Gravis Crisis
  • Myasthenia Gravis Exacerbations
  • Myasthenia Gravis Generalised
  • Myasthenia Gravis Generalized
  • Myasthenia Gravis, Generalized
  • Myasthenia Gravis, MuSK
  • Myasthenia Gravis, Ocular
  • Myasthenia Gravis, Thymectomy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time. The main questions the registry aims to answer are: * How do symptoms, daily functioning, and quality of life change over time? * What treatments do participants use, and how are these treatments related to their symptoms and health? * What challenges do participants experience with treatment, including side effects, treatment burden, missed doses, and access to care? Participants will: * Join the registry and complete an enrollment survey (online or through a mobile app) * Complete a brief online survey about their MG approximately once a month * Provide information that can help confirm their MG diagnosis * Optionally, share their medical records with the research team This is an observational study. The registry will not assign treatments or ask participants to change their medical care. Information collected through the registry may help researchers better understand MG and improve future research and care.

Key Dates

First listed
Aug 12, 2026
Start date
Mar 19, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2036
Completion
Mar 31, 2036

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Myasthenia Gravis (MG)
    Adults with confirmed diagnosis of MG

Primary Outcome Measure

MG-ADL [ Time Frame: through study completion, up to 10 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Alira Health - Virtual/Remote Site - Can Be Completed 100% Online - All US Residents AcceptedFraminghamMassachusetts01702
AXIS Patient Registry Team - US
[email protected]
765-632-2517
President, Board of Directors, Autoimmune Neurology Alliance
[email protected]
Jared R Adams, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Framingham, MA

By research site
Alira Health - Virtual/Remote Site - Can Be Completed 100% Online - All US Residents Accepted· Framingham, MA

Related Studies